Abstract: Venetoclax-based therapies combined with either a DNA methyltransferase inhibitor or low-dose cytarabine have become the standard frontline treatment for older or unfit …
Abstract: Multiple clinical trials have demonstrated significant cardiovascular benefit with use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 …